Accuray Announces Approval of the Tomo® C Radiation Treatment Delivery System by China's National Medical Products Administration PR Newswire MADISON, Wis., Oct. 3, 2023 MADISON, Wis.,...
CAMBRIDGE, Mass., Oct. 03, 2023 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage cell and genome engineering company, today announced that,...
The two companies also shared next steps in their drug testing regimens. The post Atai, Cybin Give Positive Psychedelic Drug Study Updates appeared first...
Atai Life Sciences has completed its Phase 1 study of VLS-01, an oral DMT for treatment-resistant depression (TRD). The post atai Life Sciences Completes...
The randomized pivotal Phase 3 study is expected to enroll a total of 354 patients in either Bria-IMT™ combination or physician’s choice therapy (1:1)Positive...
We’re already into the final quarter of the year and what a year this has been! We embarked on the year with worries about inflation and...
Media Release SYDNEY, AUSTRALIA, Oct. 03, 2023 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) (“Immutep” or “the Company”),...
As economic and stock market uncertainty looms, you may think at first that now is not a great time to be dabbling in speculative stocks. Yet,...
MDNA223 is a bifunctional Superkine designed to activate cancer-killing immune cells via the IL-2 receptor while simultaneously preventing their exhaustion...
REYKJAVIK, Iceland and PISCATAWAY, N.J., Oct. 03, 2023 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development...